IP Library Patent Application 11594891
Patent Application
App. No. 11/594,891

Formulations of fispemifene

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/594,891
Abstract

This invention relates to a liquid or semisolid oral drug formulation comprising a therapeutically active compound of the formula (I) or a geometric isomer, a stereoisomer, a mixture of isomers, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, in combination with a pharmaceutically acceptable carrier.

Claims (13)

1 . A liquid or semisolid oral drug formulation comprising a therapeutically active compound of the formula (I)

or a geometric isomer, a stereoisomer, a mixture of isomers, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, in combination with a pharmaceutically acceptable carrier.

2 . The drug formulation according to claim 1 wherein compound (I) is fispemifene.

3 . The drug formulation according to claim 1 wherein said formulation is selected from the group consisting of a solution, a suspension and a combination of a solution and suspension.

4 . The drug formulation according to claim 1 wherein said therapeutically active compound is dissolved and/or suspended in an oil.

5 . The drug formulation according to claim 1 wherein said formulation is an emulsion.

6 . The drug formulation according to claim 5 wherein the emulsion is a microemulsion or nanoemulsion.

7 . The drug formulation according to claim 1 wherein the formulation is a syrup.

8 . The drug formulation according to claim 1 wherein the formulation is a gel.

9 . The drug formulation according to claim 1 wherein the formulation is a paste.

10 . The drug formulation according to claim 1 wherein said formulation is packed into a unit dosage form.

11 . The drug formulation according to claim 10 wherein the dosage form is the formulation encapsulated in a soft capsule.

12 . The drug formulation according to claim 1 wherein the carrier comprises a bile flow promoting agent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2006
From: LEHTOLA, VELI-MATTI; HALONEN, KAIJA
To: HORMOS MEDICAL LTD.
Reel/Frame 018538/0210 →